Teladoc Health (NYSE:TDOC) Issues Earnings Results

Teladoc Health (NYSE:TDOC) issued its quarterly earnings results on Wednesday. The health services provider reported ($0.36) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.02), FiscalAI reports. Teladoc Health had a negative return on equity of 11.32% and a negative net margin of 6.81%.The business had revenue of $613.85 million during the quarter, compared to analyst estimates of $610.87 million. During the same period in the previous year, the business posted ($0.53) earnings per share. The firm’s quarterly revenue was down 2.5% on a year-over-year basis. Teladoc Health updated its FY 2026 guidance to -1.050–0.750 EPS and its Q2 2026 guidance to -0.300–0.200 EPS.

Here are the key takeaways from Teladoc Health’s conference call:

• Consolidated results beat guidance — Q1 revenue $614M and adjusted EBITDA $58M, with $751M in cash and net debt/adjusted EBITDA below 0.9x, signaling near-term financial strength.
• Integrated Care showed steady growth and margin expansion — revenue $395M (+1.5% YoY) and adjusted EBITDA $56M (14.2% margin); management expects the shift from subscriptions to visit-based care and new AI-enabled, enhanced 24/7 offerings to become a net tailwind in H2.
• BetterHelp insurance rollout is ahead of plan — live in 30 states + DC, >6,000 credentialed providers, >150M insured lives, and insurance sessions >14,000/week; company now expects to exit 2026 with a BetterHelp insurance run-rate of at least $125M.
• BetterHelp’s direct-to-consumer business remains pressured — Q1 revenue declined 9% YoY to $218M, average paying users fell 9%, and adjusted EBITDA was only $2M (0.9% margin) as cash-pay weakness and insurance-scaling investments weighed on profitability.
• Management reiterated full-year 2026 guidance (revenue $2.48B–$2.58B; adj EBITDA $267M–$306M; FCF $130M–$170M), plans a two-phase approach to reduce 2027 convertible-related gross debt, and expects stock-based comp to fall below $55M, indicating disciplined capital and cost management.

Teladoc Health Trading Up 6.4%

Shares of NYSE TDOC traded up $0.39 during midday trading on Friday, hitting $6.45. The stock had a trading volume of 7,419,516 shares, compared to its average volume of 5,985,491. The company has a fifty day moving average price of $5.40 and a 200 day moving average price of $6.46. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -6.68 and a beta of 2.07. The company has a quick ratio of 2.67, a current ratio of 2.77 and a debt-to-equity ratio of 0.72. Teladoc Health has a 1-year low of $4.40 and a 1-year high of $9.77.

Key Headlines Impacting Teladoc Health

Here are the key news stories impacting Teladoc Health this week:

• Positive Sentiment: Unusually large call buying — traders bought ~28,675 call options on Friday (about 102% above average), indicating increased bullish positioning or speculative interest that can amplify upside momentum in the stock.
• Positive Sentiment: Narrower Q1 net loss and signs of operating tightening — Teladoc reported a smaller GAAP loss (down to ~$63.8M from ~$93M a year ago) and management emphasized cost discipline and progress toward breakeven, which supports a more constructive investment narrative. How Teladoc’s Narrower Q1 Loss Amid Softer Revenue Has Changed Its Investment Story
• Positive Sentiment: FY revenue guidance skewed to the upside — Teladoc gave full-year revenue guidance range modestly above consensus, suggesting confidence in annual revenue recovery even as quarters may fluctuate; that outlook can be supportive for medium-term valuation. Teladoc Health Reports First Quarter 2026 Results
• Neutral Sentiment: Revenue narrowly beat estimates but remains down year-over-year (~$613.8M, -2.5% YoY) — a mixed signal: beat vs. Street yet continued top-line pressure. Q1 2026 Press Release (Teladoc)
• Neutral Sentiment: Analyst and sector write-ups (Hims & Hers comparison) are exploring relative upside and strategy differences, which may influence sentiment but aren’t direct catalysts. HIMS vs. TDOC: Which Digital Health Stock Offers Better Upside Now?
• Negative Sentiment: EPS missed modestly (reported -$0.36 vs consensus -$0.34) and management lowered EPS guidance for FY and set a Q2 EPS range that implies continued losses, both worse than Street expectations — this raises short-term valuation risk. MarketBeat: Teladoc Earnings
• Negative Sentiment: Q2 revenue guidance came in below consensus, and analysts flagged cash flow and business-model transition concerns on the call — near-term growth headwinds could pressure the stock if execution slips. Teladoc Surprises With Q1 Sales But Stock Drops Q1 Call Highlights

Insider Buying and Selling

In related news, CEO Charles Divita III sold 27,731 shares of the business’s stock in a transaction that occurred on Wednesday, March 11th. The stock was sold at an average price of $5.49, for a total transaction of $152,243.19. Following the transaction, the chief executive officer directly owned 364,784 shares of the company’s stock, valued at approximately $2,002,664.16. The trade was a 7.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Company insiders own 0.70% of the company’s stock.

Hedge Funds Weigh In On Teladoc Health

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Syon Capital LLC lifted its position in Teladoc Health by 19.1% during the 4th quarter. Syon Capital LLC now owns 14,140 shares of the health services provider’s stock worth $99,000 after acquiring an additional 2,264 shares in the last quarter. HighTower Advisors LLC lifted its position in Teladoc Health by 19.2% during the 4th quarter. HighTower Advisors LLC now owns 18,647 shares of the health services provider’s stock worth $131,000 after acquiring an additional 2,997 shares in the last quarter. Polymer Capital Management US LLC acquired a new position in Teladoc Health during the 3rd quarter worth approximately $131,000. Entropy Technologies LP acquired a new position in Teladoc Health during the 3rd quarter worth approximately $133,000. Finally, Quantitative Investment Management LLC lifted its position in Teladoc Health by 40.3% during the 3rd quarter. Quantitative Investment Management LLC now owns 17,799 shares of the health services provider’s stock worth $137,000 after acquiring an additional 5,114 shares in the last quarter. 76.82% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. TD Cowen decreased their price target on Teladoc Health from $8.00 to $6.00 and set a “hold” rating on the stock in a research note on Thursday, February 26th. Wells Fargo & Company reduced their price objective on Teladoc Health from $8.00 to $6.00 and set an “equal weight” rating on the stock in a research note on Thursday, February 26th. Barclays reduced their price objective on Teladoc Health from $8.50 to $7.00 and set an “equal weight” rating on the stock in a research note on Thursday, March 26th. Piper Sandler reaffirmed an “overweight” rating and issued a $9.00 price objective (down from $12.00) on shares of Teladoc Health in a research note on Thursday, February 26th. Finally, Canaccord Genuity Group reduced their price objective on Teladoc Health from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Thursday, February 26th. Five analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus target price of $7.47.

About Teladoc Health

Teladoc Health, Inc is a leading global provider of virtual healthcare services, offering on-demand medical consultations via phone, video, and mobile app platforms. The company connects patients with licensed physicians and specialists for non-emergency medical issues, mental health support, dermatology, and chronic condition management. By leveraging digital technologies and data analytics, Teladoc aims to enhance accessibility, reduce healthcare costs, and improve patient outcomes through personalized care plans and remote monitoring.

Teladoc’s service portfolio includes general medical visits, behavioral health sessions, expert medical services for complex cases, and wellness programs designed to support chronic disease management such as diabetes, hypertension, and heart disease.